Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10014326HBVENSG00000082175.16protein_codingPGRYesNo5241P06401
TVIS30086512HIVENSG00000082175.16protein_codingPGRYesNo5241P06401
TVIS20022380HPVENSG00000082175.16protein_codingPGRYesNo5241P06401
TVIS20049966HPVENSG00000082175.16protein_codingPGRYesNo5241P06401
TVIS20049934HPVENSG00000082175.16protein_codingPGRYesNo5241P06401
TVIS44013458HTLV-1ENSG00000082175.16protein_codingPGRYesNo5241P06401
TVIS44020347HTLV-1ENSG00000082175.16protein_codingPGRYesNo5241P06401
TCGA Plot Options
Drug Information
GenePGR
DrugBank IDDB00421
Drug NameSpironolactone
Target IDBE0000557
UniProt IDP06401
Regulation Typeagonist
PubMed IDs20650892; 6849751
CitationsFagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, Pook E, Schafer S, Rafestin-Oblin ME, Kolkhof P: A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22.@@Fernandez MD, Carter GD, Palmer TN: The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol. Br J Clin Pharmacol. 1983 Jan;15(1):95-101. doi: 10.1111/j.1365-2125.1983.tb01470.x.
GroupsApproved
Direct ClassificationSpironolactones and derivatives
SMILES[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O
PathwaysSpironolactone Action Pathway
PharmGKBPA451483
ChEMBLCHEMBL1393